MYC and neoplasm: Accordingly, tumor cells co-expressing c-Myc are more sensitive to FGFR inhibition [126] and c-Myc alteration can determine the therapeutic response to FGFR inhibitors [42], strongly suggesting that c-Myc is an important downstream mediator of the FGF/FGFR signaling.